CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

On March 6, 2023, CTI BioPharma Corp. (Nasdaq: CTIC) announced that its Compensation Committee granted equity inducement awards to five new employees, totaling options for 148,000 shares of common stock. These awards, approved under Nasdaq Listing Rule 5635(c)(4), are critical for the employees' acceptance of employment. The stock options will have an exercise price equal to the closing price on the Grant Date and will vest over four years, contingent on the employees' continued employment. CTI BioPharma focuses on developing therapies for blood-related cancers, including the FDA-approved product VONJO, aimed at treating myelofibrosis.

Positive

Equity inducement awards could attract skilled employees, enhancing company talent.
Total of 148,000 stock options granted may align employee interests with shareholders.

Negative

None.

Argus Session date unavailable

-1.66% session move Open Argus

Details

News Market Reaction – CTIC

The recorded move for CTIC in the trading session of this news was -1.66%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/06/2023 - 04:35 PM EST

SEATTLE, March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on March 6, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received options to purchase an aggregate of 148,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

About CTI BioPharma Corp.

CTI BioPharma is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO^® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. For more information, please visit www.ctibiopharma.com.

VONJO^® is a registered trademark of CTI BioPharma Corp.

Investor Relations and Media Contacts:

Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301763831.html

SOURCE CTI BioPharma Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards were granted by CTI BioPharma on March 6, 2023?

CTI BioPharma granted equity inducement awards totaling options for 148,000 shares of common stock to five new employees.

How do the stock options from the recent grant vest?

The stock options will vest one-fourth on each anniversary of the Grant Date, contingent on the employees' continued employment.

Under which rule did CTI BioPharma grant equity awards?

The equity awards were approved under Nasdaq Listing Rule 5635(c)(4).

What is the significance of the equity awards for new employees?

The equity awards are material for the employees' acceptance of employment, potentially attracting skilled talent.

What is CTI BioPharma's focus in the biopharmaceutical sector?

CTI BioPharma specializes in developing targeted therapies for blood-related cancers.

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)